

EurobioPlex FluABCoSyn

Multiplex detection of SARS-CoV-2, Influenza A and Influenza B viruses and RSV.

Real-time RT-PCR for surveillance of respiratory infections.

One-step RT-PCR¹

4 targets,
1 reaction

Viral differentiation¹

SARS-CoV-2 vs
Influenza vs RSV

Reduction of false negatives¹

Integrated endogenous
control



CLINICAL CONTEXT

SARS-CoV-2, responsible for the COVID-19 pandemic, has caused more than 6.9 million deaths worldwide since the end of 2019, with an estimated case-fatality rate of around 0.15% according to aggregated international data². Seasonal influenza causes around 1 billion infections a year, including 3 to 5 million severe cases and up to 650,000 respiratory deaths, mainly in at-risk populations (elderly subjects, pregnant women, people with comorbidities)³.

Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections in infants, with 33 million cases, 3.6 million hospitalizations and over 100,000 deaths annually in children under 5 years of age, the vast majority in low- and middle-income countries⁴.

Accurate differentiation is essential to guide management and limit transmission.

DIAGNOSTIC

Real-time RT-PCR is the reference method for the qualitative detection of SARS-CoV-2, Influenza A/B viruses and RSV, particularly in patients with similar respiratory symptoms requiring rapid differential diagnosis.

A comparative clinical study showed that multiplex RT-PCR tests have >92% concordance in sensitivity and specificity and no cross-reactivity with other common respiratory pathogens⁵.

Key features¹

Test principle	Real-time multiplex RT-PCR test for the qualitative detection of respiratory RNA viruses.
Sample type	RNA extract from a nasopharyngeal swab.
Targets detected	SARS-CoV-2 (RdRp1 and RdRp2 genes) / Influenza A / Influenza B / Respiratory Syncytial Virus A and B (RSV A/B)
Detection limits (at 95% probability)	SARS-CoV-2 : 4,02 copies/μL Influenza A : 19,81 copies/μL Influenza B : 19,81 copies/μL VRS A/B : 10,93 copies/μL

Performances¹

Overall performance is as follows:

	Sensitivity	Specificity	Concordance
FLU A	90%	>99%	95%
FLU B	>99%	>99%	>99%
RSV	>99%	>99%	>99%
SARS-Cov-2	>99%	>99%	>99%

References	Name	Format
EBX-066	EurobioPlex FluABCoSyn	50/100/ 200/600 tests

1. For further information, please refer to the instruction manual.

2. Ioannidis JPA. Bull World Health Organ. 2021;99(1):19–33F.

3. World Health Organization (WHO). Influenza (Seasonal). Fact sheet. Disponible on : [https://www.who.int/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal))

4. World Health Organization (WHO). Respiratory Syncytial Virus (RSV). Fact sheet. Disponible on : [https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-\(rsv\)](https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv))

5. J Korean Med Sci. 2021;36(48):e328.